Exhibit 99.1

                        FDA Approves Critical
  Therapeutics' Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release
                          Tablets for Asthma

   Sales Force of 240 Representatives to Market ZYFLO CR in the U.S.

    LEXINGTON, Mass.--(BUSINESS WIRE)--May 31, 2007--Critical
Therapeutics, Inc. (Nasdaq: CRTX) announced today that the U.S. Food
and Drug Administration (FDA) has approved the Company's New Drug
Application (NDA) for twice-daily ZYFLO CR(TM)(zileuton)
extended-release tablets. Critical Therapeutics, together with its
co-promotion partner Dey, L.P. (DEY), expects to begin marketing ZYFLO
CR in the U.S. in the fall of 2007.

    ZYFLO CR and ZYFLO(R) (zileuton tablets) are the only FDA-approved
leukotriene synthesis inhibitors for the prophylaxis and chronic
treatment of asthma in adults and children 12 years of age and older.
ZYFLO CR and ZYFLO are not indicated for use in the reversal of
bronchospasm in acute asthma attacks, but can be continued during
acute exacerbations of asthma. Leukotrienes are inflammatory mediators
in asthma that can trigger asthma symptoms, including inflammation,
swelling, bronchoconstriction and mucus secretion. ZYFLO CR uses
SkyePharma PLC's (LSE: SKP) proprietary Geomatrix(R) drug delivery
technology, which controls the amount and rate of drug released into
the body.

    "This approval is an exciting milestone for Critical Therapeutics
because it solidifies our position in the asthma market and completes
an important step to strengthen the Company and rebuild shareholder
value," said Frank Thomas, Critical Therapeutics' president and chief
executive officer. "Supported by our co-promotion partnership with
DEY, I believe that ZYFLO CR's twice daily dosing regimen will allow
us to establish it as an important option in the asthma market and
significantly expand our patient base."

    "With its unique mechanism of action as a leukotriene synthesis
inhibitor and its twice-daily dosing, ZYFLO CR could effectively
manage patients whose symptoms are not adequately controlled," said
Sally Wenzel, M.D., an investigator for ZYFLO CR and ZYFLO and
Professor at the University of Pittsburgh. "Despite available current
asthma therapies, uncontrolled asthma still impacts a large number of
Americans. ZYFLO CR could potentially provide improved symptom control
for those patients who still struggle day-to-day to control their
asthma."

    In March 2007, Critical Therapeutics and DEY, an affiliate of
Germany-based Merck GKaA, entered into an agreement for the
co-promotion of ZYFLO CR and ZYFLO, the immediate-release formulation
of zileuton. DEY's 200-person sales force began promoting ZYFLO on
April 30, 2007. Upon the launch of ZYFLO CR, the Company and DEY's
combined sales force of 240 representatives will begin promoting ZYFLO
CR to approximately 15,000 allergists, pulmonologists and primary care
physicians across the U.S.

    About ZYFLO CR and ZYFLO

    ZYFLO CR and ZYFLO are the only FDA-approved leukotriene synthesis
inhibitors for the prophylaxis and chronic treatment of asthma in
adults and children 12 years of age and older. ZYFLO CR and ZYFLO are
not indicated for use in the reversal of bronchospasm in acute asthma
attacks. Therapy with ZYFLO CR and ZYFLO can be continued during acute
exacerbations of asthma.

    The recommended dose of ZYFLO CR is two 600 mg extended-release
tablets twice daily, within one hour after morning and evening meals,
for a total daily dose of 2400 mg. The recommended dose of ZYFLO is
one 600 mg immediate-release tablet four times a day for a total daily
dose of 2400 mg.

    ZYFLO CR and ZYFLO are contraindicated in patients with active
liver disease or transaminase elevations greater than or equal to
three times the upper limit of normal. A small percentage of patients
treated with ZYFLO CR (2.5%) and ZYFLO (1.9%) in placebo-controlled
trials showed an increased release of a liver enzyme known as ALT and
bilirubin (an orange or yellowish pigment in bile). As a result, the
level of liver enzymes in patients treated with ZYFLO CR and ZYFLO
should be measured by a simple blood test. It is recommended that
physicians perform this test before administering ZYFLO CR and ZYFLO
and repeat the test on a regular basis while patients are on the
medication. Patients taking ZYFLO CR and theophylline should reduce
the theophylline dose by 50%. Patients taking ZYFLO CR and propranolol
or warfarin should be monitored and doses adjusted as appropriate.
Most common side effects associated with the use of ZYFLO CR and ZYFLO
are sinusitis, nausea and pharyngolaryngeal pain and abdominal pain,
upset stomach and nausea, respectively.

    For full prescribing information for ZYFLO CR, please visit
www.zyflocr.com or call the Company's toll free telephone number
1-866-835-8216 to request medical information.

    For full prescribing information for ZYFLO, please visit
www.zyflo.com or call the Company's toll free telephone number
1-866-835-8216 to request medical information.

    About Critical Therapeutics

    Critical Therapeutics, Inc. is developing and commercializing
innovative products for respiratory, inflammatory and critical care
diseases. The Company owns worldwide rights to two FDA-approved drugs
for the prevention and chronic treatment of asthma in patients 12
years of age and older: twice-daily ZYFLO CR(TM) (zileuton)
extended-release tablets and ZYFLO(R) (zileuton tablets). Critical
Therapeutics is working to develop products for acute asthma attacks
that lead patients to the emergency room and other urgent care
settings. The Company also is developing therapies directed toward the
body's inflammatory response. Critical Therapeutics is located in
Lexington, Mass. For more information, please visit www.crtx.com.

    Forward-Looking Statements

    Any statements in this press release about future expectations,
plans and prospects for Critical Therapeutics, Inc., including,
without limitation, statements regarding possible therapeutic
benefits, market acceptance and future sales of ZYFLO CR; the
anticipated success of the co-promotion arrangement with DEY; the
progress, timing and success of the product launch for ZYFLO CR;
prospects, plans and objectives of management; and all other
statements that are not purely historical in nature, constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Without limiting the
foregoing, the words "anticipate," "believe," "could," "estimate,"
"expect," "intend," "may," "plan," "project," "should," "will,"
"would" and similar expressions are intended to identify
forward-looking statements. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including risks and uncertainties relating
to: our ability to successfully market and sell ZYFLO CR, including
the success of our co-promotion arrangement with DEY; our ability to
develop and maintain the necessary sales, marketing, distribution and
manufacturing capabilities to commercialize ZYFLO CR; patient,
physician and third-party payor acceptance of ZYFLO CR as a safe and
effective therapeutic product; adverse side effects experienced by
patients taking ZYFLO CR; our heavy dependence on the commercial
success of ZYFLO CR; our ability to maintain regulatory approvals to
market and sell ZYFLO CR; our ability to successfully enter into
additional strategic co-promotion, collaboration or licensing
transactions on favorable terms, if at all; conducting clinical
trials, including difficulties or delays in the completion of patient
enrollment, data collection or data analysis; our ability to obtain
the substantial additional funding required to conduct our research,
development and commercialization activities; our dependence on our
strategic collaboration with MedImmune, Inc.; and our ability to
obtain, maintain and enforce patent and other intellectual property
protection for ZYFLO, ZYFLO CR, our discoveries and our drug
candidates. These and other risks are described in greater detail in
the "Risk Factors" section of our most recent Quarterly Report on Form
10-Q and other filings that we make with the Securities and Exchange
Commission. If one or more of these factors materialize, or if any
underlying assumptions prove incorrect, our actual results,
performance or achievements may vary materially from any future
results, performance or achievements expressed or implied by these
forward-looking statements.

    In addition, the statements in this press release reflect our
expectations and beliefs as of the date of this release. We anticipate
that subsequent events and developments will cause our expectations
and beliefs to change. However, while we may elect to update these
forward-looking statements publicly at some point in the future, we
specifically disclaim any obligation to do so, whether as a result of
new information, future events or otherwise. These forward-looking
statements should not be relied upon as representing our views as of
any date subsequent to the date of this release.

    ZYFLO(R) is a registered trademark of Critical Therapeutics, Inc.,
ZYFLO CR(TM) is a trademark of Critical Therapeutics, Inc.,
GEOMATRIX(R) is a registered trademark of SkyePharma PLC.

    CONTACT: Critical Therapeutics, Inc.
             Linda S. Lennox, 781-402-5708
             Vice President, Investor & Media Relations
             llennox@crtx.com